Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009812 | 0.95 | POLB (0.50) | TP53RAB9AMAPTPOLBHTT | |
| SCHEMBL3006654 | 0.91 | POLB (0.53) | TP53RAB9APOLBHTTCNR2 | |
| SCHEMBL4083893 | 0.90 | CNR2 (0.50) | TP53RAB9AMAPTPOLBEPHX1 | |
| SCHEMBL3006153 | 0.90 | TP53 (0.54) | TP53RAB9APOLBEPHX1CNR2 | |
| SCHEMBL2996526 | 0.89 | KMT2A (0.51) | RAB9APOLBCNR2KMT2AFAAH | |
| SCHEMBL3000341 | 0.89 | TP53 (0.52) | TP53RAB9APOLBEPHX1CNR2 | |
| SCHEMBL2992971 | 0.88 | FAAH (0.57) | TP53RAB9AMAPTPOLBHTT | |
| SCHEMBL4089843 | 0.88 | MAPT (0.47) | TP53RAB9AMAPTPOLBHTT | |
| SCHEMBL3004122 | 0.86 | TP53 (0.50) | TP53RAB9APOLBEPHX1KMT2A | |
| SCHEMBL2998814 | 0.85 | LMNA (0.51) | TP53RAB9AMAPTPOLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | TP53 4734/4885RAB9A 2477/4885MAPT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.